|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.395 USD | -14.13% |
|
-43.57% | -97.38% |
| May. 14 | Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 10 | Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc. | CI |
Acorda Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 20.29 million compared to USD 22.26 million a year ago. Net loss was USD 27.4 million compared to USD 16.82 million a year ago.
Basic loss per share from continuing operations was USD 22.06 compared to USD 13.54 a year ago. Diluted loss per share from continuing operations was USD 22.06 compared to USD 13.54 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -97.38% | 491K | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.26% | 21.96B | |
| -8.24% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
ACORDA THERAPEUTICS, INC. 
